1. Cancer Biology
  2. Computational and Systems Biology

Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate

  1. Malene Juul  Is a corresponding author
  2. Johanna Bertl
  3. Qianyun Guo
  4. Morten Muhlig Nielsen
  5. Michał Świtnicki
  6. Henrik Hornshøj
  7. Tobias Madsen
  8. Asger Hobolth
  9. Jakob Skou Pedersen  Is a corresponding author
  1. Aarhus University Hospital, Denmark
  2. Aarhus University, Denmark
https://doi.org/10.7554/eLife.21778
Share this article
Cite this article
  1. Malene Juul
  2. Johanna Bertl
  3. Qianyun Guo
  4. Morten Muhlig Nielsen
  5. Michał Świtnicki
  6. Henrik Hornshøj
  7. Tobias Madsen
  8. Asger Hobolth
  9. Jakob Skou Pedersen
(2017)
Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate
eLife 6:e21778.
https://doi.org/10.7554/eLife.21778
  2. Download BibTeX
  3. Download .RIS

Abstract

Non-coding mutations may drive cancer development. Statistical detection of non-coding driver regions is challenged by a varying mutation rate and uncertainty of functional impact. Here we develop a statistically-founded non-coding driver-detection method, ncdDetect, which includes sample-specific mutational signatures, long-range mutation rate variation, and position-specific impact measures. Using ncdDetect, we screened non-coding regulatory regions of protein-coding genes across a pan-cancer set of whole-genomes (n=505), which top-ranked known drivers and identified new candidates. For individual candidates, presence of non-coding mutations associate with altered expression or decreased patient survival across an independent pan-cancer sample set (n=5,454). This includes an antigen-presenting gene (CD1A), where 5'UTR mutations correlate significantly with decreased survival in melanoma. Additionally, mutations in a base-excision-repair gene (SMUG1) correlate with a C-to-T mutational-signature. Overall, we find that a rich model of mutational heterogeneity facilitates non-coding driver identification and integrative analysis points to candidates of potential clinical relevance.

Article and author information

Author details

  1. Malene Juul

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    For correspondence
    malene.juul.rasmussen@clin.au.dk
    Competing interests
    The authors declare that no competing interests exist.

  2. Johanna Bertl

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  3. Qianyun Guo

    Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  4. Morten Muhlig Nielsen

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  5. Michał Świtnicki

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  6. Henrik Hornshøj

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  7. Tobias Madsen

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  8. Asger Hobolth

    Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
    Competing interests
    The authors declare that no competing interests exist.

  9. Jakob Skou Pedersen

    Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
    For correspondence
    jakob.skou@clin.au.dk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7236-4001

Funding

Medical Sciences (Sapere Aude Grant,#12-126439)

  • Jakob Skou Pedersen

The Danish Council for Strategic Research (#10-092320/DSF)

  • Jakob Skou Pedersen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Gilean McVean, Oxford University, United Kingdom

Version history

  1. Received: September 24, 2016
  2. Accepted: March 14, 2017
  3. Accepted Manuscript published: March 31, 2017 (version 1)
  4. Accepted Manuscript updated: April 7, 2017 (version 2)
  5. Version of Record published: May 22, 2017 (version 3)

Copyright

© 2017, Juul et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,136
    views
  • 605
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Malene Juul
  2. Johanna Bertl
  3. Qianyun Guo
  4. Morten Muhlig Nielsen
  5. Michał Świtnicki
  6. Henrik Hornshøj
  7. Tobias Madsen
  8. Asger Hobolth
  9. Jakob Skou Pedersen
(2017)
Non-coding cancer driver candidates identified with a sample- and position-specific model of the somatic mutation rate
eLife 6:e21778.
https://doi.org/10.7554/eLife.21778

Share this article

https://doi.org/10.7554/eLife.21778

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Cell Biology

    A syngeneic spontaneous zebrafish model of tp53-deficient, EGFRvIII, and PI3KCAH1047R-driven glioblastoma reveals inhibitory roles for inflammation during tumor initiation and relapse in vivo

    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.

    1. Cancer Biology
    2. Cell Biology

    Cancer: Modeling glioblastoma

    Ian Lorimer
    Insight

    Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.

    1. Cancer Biology

    YAP/TAZ enhances P-body formation to promote tumorigenesis

    Xia Shen, Xiang Peng ... Chen-Ying Liu
    Research Article

    The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes SAMD4A, AJUBA, and WTIP and transcriptional suppression of the tumor suppressor gene PNRC1 are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (DDX6, DCP1A, and LSM14A), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP5SA in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of SAMD4A, AJUBA, WTIP, PNRC1, and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.